Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 32 entries
Sorted by: Best Match Show Resources per page
The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic.

American journal of therapeutics

Drayer JI, Stimpel M, Fox A, Weber M.
PMID: 11854821
Am J Ther. 1995 Aug;2(8):525-531. doi: 10.1097/00045391-199508000-00002.

The antihypertensive characteristics of the angiotensin-converting enzyme inhibitor moexipril were evaluated in 413 patients with baseline setting diastolic blood pressures between 95 and 114 mm Hg. The study was double blind, with patients randomized to placebo or to differing...

Cite
Drayer JI, Stimpel M, Fox A, et al. The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. Am J Ther. 1995;2(8):525-531doi: 10.1097/00045391-199508000-00002.
Drayer, J. I., Stimpel, M., Fox, A., & Weber, M. (1995). The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. American journal of therapeutics, 2(8), 525-531. https://doi.org/10.1097/00045391-199508000-00002
Drayer, Jan I.M., et al. "The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic." American journal of therapeutics vol. 2,8 (1995): 525-531. doi: https://doi.org/10.1097/00045391-199508000-00002
Drayer JI, Stimpel M, Fox A, Weber M. The Antihypertensive Properties of the Angiotensin-Converting Enzyme Inhibitor Moexipril Given Alone or in Combination with a Low Dose of a Diuretic. Am J Ther. 1995 Aug;2(8):525-531. doi: 10.1097/00045391-199508000-00002. PMID: 11854821.
Copy Download .nbib Format: NLM
Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.

Annals of surgical oncology

Mamtani A, Patil S, Stempel M, Morrow M.
PMID: 28718032
Ann Surg Oncol. 2017 Dec;24:691-692. doi: 10.1245/s10434-017-6004-2.

No abstract available.

Cite
Mamtani A, Patil S, Stempel M, et al. Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Ann Surg Oncol. 2017;24:691-692doi: 10.1245/s10434-017-6004-2.
Mamtani, A., Patil, S., Stempel, M., & Morrow, M. (2017). Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Annals of surgical oncology, 24691-692. https://doi.org/10.1245/s10434-017-6004-2
Mamtani, Anita, et al. "Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer." Annals of surgical oncology vol. 24 (2017): 691-692. doi: https://doi.org/10.1245/s10434-017-6004-2
Mamtani A, Patil S, Stempel M, Morrow M. Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer. Ann Surg Oncol. 2017 Dec;24:691-692. doi: 10.1245/s10434-017-6004-2. PMID: 28718032.
Copy Download .nbib Format: NLM
Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?.

Annals of surgical oncology

Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio AV, Morrow M.
PMID: 32086652
Ann Surg Oncol. 2020 Dec;27:966. doi: 10.1245/s10434-020-08273-4.

The following are corrections to the original article.

Cite
Moo TA, Edelweiss M, Hajiyeva S, et al. Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. Ann Surg Oncol. 2020;27:966doi: 10.1245/s10434-020-08273-4.
Moo, T. A., Edelweiss, M., Hajiyeva, S., Stempel, M., Raiss, M., Zabor, E. C., Barrio, A. V., & Morrow, M. (2020). Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. Annals of surgical oncology, 27966. https://doi.org/10.1245/s10434-020-08273-4
Moo, Tracy-Ann, et al. "Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?." Annals of surgical oncology vol. 27 (2020): 966. doi: https://doi.org/10.1245/s10434-020-08273-4
Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio AV, Morrow M. Correction to: Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?. Ann Surg Oncol. 2020 Dec;27:966. doi: 10.1245/s10434-020-08273-4. PMID: 32086652.
Copy Download .nbib Format: NLM
Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation.

Frontiers in pharmacology

Stümpel FT, Stein J, Himmler K, Scholz B, Seidl MD, Skryabin BV, Müller FU.
PMID: 30026696
Front Pharmacol. 2018 Jul 05;9:706. doi: 10.3389/fphar.2018.00706. eCollection 2018.

No abstract available.

Cite
Stümpel FT, Stein J, Himmler K, et al. Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation. Front Pharmacol. 2018;9:706doi: 10.3389/fphar.2018.00706.
Stümpel, F. T., Stein, J., Himmler, K., Scholz, B., Seidl, M. D., Skryabin, B. V., & Müller, F. U. (2018). Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation. Frontiers in pharmacology, 9706. https://doi.org/10.3389/fphar.2018.00706
Stümpel, Frank T, et al. "Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation." Frontiers in pharmacology vol. 9 (2018): 706. doi: https://doi.org/10.3389/fphar.2018.00706
Stümpel FT, Stein J, Himmler K, Scholz B, Seidl MD, Skryabin BV, Müller FU. Homozygous CREM-IbΔC-X Overexpressing Mice Are a Reliable and Effective Disease Model for Atrial Fibrillation. Front Pharmacol. 2018 Jul 05;9:706. doi: 10.3389/fphar.2018.00706. eCollection 2018. PMID: 30026696; PMCID: PMC6041408.
Copy Download .nbib Format: NLM
Prevalence and Social-Ecological Correlates of Intimate Partner Violence in a Conflict Zone-Evidence From the 2015 Afghanistan Demographic and Health Survey.

Violence against women

Alemi Q, Stempel C, Montgomery S, Koga PM, Smith V, Baek K, Fisher CC, Malika N.
PMID: 34894891
Violence Against Women. 2021 Dec 13;10778012211051398. doi: 10.1177/10778012211051398. Epub 2021 Dec 13.

This study examined the prevalence and social-ecological correlates of male-to-female intimate partner violence (IPV) in Afghanistan. Using data from the 2015 Afghanistan Demographic and Health Survey, which included 20,793 currently married women, we found that the past-year prevalence of...

Cite
Alemi Q, Stempel C, Montgomery S, et al. Prevalence and Social-Ecological Correlates of Intimate Partner Violence in a Conflict Zone-Evidence From the 2015 Afghanistan Demographic and Health Survey. Violence Against Women. 2021;10778012211051398doi: 10.1177/10778012211051398.
Alemi, Q., Stempel, C., Montgomery, S., Koga, P. M., Smith, V., Baek, K., Fisher, C. C., & Malika, N. (2021). Prevalence and Social-Ecological Correlates of Intimate Partner Violence in a Conflict Zone-Evidence From the 2015 Afghanistan Demographic and Health Survey. Violence against women, 10778012211051398. https://doi.org/10.1177/10778012211051398
Alemi, Qais, et al. "Prevalence and Social-Ecological Correlates of Intimate Partner Violence in a Conflict Zone-Evidence From the 2015 Afghanistan Demographic and Health Survey." Violence against women vol. (2021): 10778012211051398. doi: https://doi.org/10.1177/10778012211051398
Alemi Q, Stempel C, Montgomery S, Koga PM, Smith V, Baek K, Fisher CC, Malika N. Prevalence and Social-Ecological Correlates of Intimate Partner Violence in a Conflict Zone-Evidence From the 2015 Afghanistan Demographic and Health Survey. Violence Against Women. 2021 Dec 13;10778012211051398. doi: 10.1177/10778012211051398. Epub 2021 Dec 13. PMID: 34894891.
Copy Download .nbib Format: NLM
Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results.

Current eye research

Hark LA, Tan CS, Kresch YS, De Moraes CG, Horowitz JD, Park L, Auran JD, Gorroochurn P, Stempel S, Maruri SC, Besagar S, Saaddine JB, Lambert BC, Pizzi LT, Sapru S, Price S, Williams OA, Cioffi GA, Liebmann JM.
PMID: 33726583
Curr Eye Res. 2021 Oct;46(10):1597-1604. doi: 10.1080/02713683.2021.1905000. Epub 2021 Apr 19.

No abstract available.

Cite
Hark LA, Tan CS, Kresch YS, et al. Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results. Curr Eye Res. 2021;46(10):1597-1604doi: 10.1080/02713683.2021.1905000.
Hark, L. A., Tan, C. S., Kresch, Y. S., De Moraes, C. G., Horowitz, J. D., Park, L., Auran, J. D., Gorroochurn, P., Stempel, S., Maruri, S. C., Besagar, S., Saaddine, J. B., Lambert, B. C., Pizzi, L. T., Sapru, S., Price, S., Williams, O. A., Cioffi, G. A., & Liebmann, J. M. (2021). Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results. Current eye research, 46(10), 1597-1604. https://doi.org/10.1080/02713683.2021.1905000
Hark, Lisa A, et al. "Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results." Current eye research vol. 46,10 (2021): 1597-1604. doi: https://doi.org/10.1080/02713683.2021.1905000
Hark LA, Tan CS, Kresch YS, De Moraes CG, Horowitz JD, Park L, Auran JD, Gorroochurn P, Stempel S, Maruri SC, Besagar S, Saaddine JB, Lambert BC, Pizzi LT, Sapru S, Price S, Williams OA, Cioffi GA, Liebmann JM. Manhattan Vision Screening and Follow-Up Study in Vulnerable Populations: 1-Month Feasibility Results. Curr Eye Res. 2021 Oct;46(10):1597-1604. doi: 10.1080/02713683.2021.1905000. Epub 2021 Apr 19. PMID: 33726583.
Copy Download .nbib Format: NLM
Arguments to Apply Epinephrine for Pocket Hematoma Reduction. The MAITRE Study.

Journal of atrial fibrillation

Ilov N, Ilov N, Nechepurenko A, Abdulkadyrov A, Paskeev D, Damrina E, Kulikova E, Terent'eva M, Stompel D, Tarasov D.
PMID: 27909508
J Atr Fibrillation. 2016 Jun 30;9(1):1391. doi: 10.4022/jafib.1391. eCollection 2016.

Pocket hematoma (PH) is a common complication of implantations of cardiac electrophysiological devices with occurring at a particularly high rate in patients on oral anticoagulation or antiplatelet treatment. Different pharmacological agents with hemostatic effect are used to avoid PH....

Cite
Ilov N, Ilov N, Nechepurenko A, et al. Arguments to Apply Epinephrine for Pocket Hematoma Reduction. The MAITRE Study. J Atr Fibrillation. 2016;9(1):1391doi: 10.4022/jafib.1391.
Ilov, N., Ilov, N., Nechepurenko, A., Abdulkadyrov, A., Paskeev, D., Damrina, E., Kulikova, E., Terent'eva, M., Stompel, D., & Tarasov, D. (2016). Arguments to Apply Epinephrine for Pocket Hematoma Reduction. The MAITRE Study. Journal of atrial fibrillation, 9(1), 1391. https://doi.org/10.4022/jafib.1391
Ilov, Nikolay, et al. "Arguments to Apply Epinephrine for Pocket Hematoma Reduction. The MAITRE Study." Journal of atrial fibrillation vol. 9,1 (2016): 1391. doi: https://doi.org/10.4022/jafib.1391
Ilov N, Ilov N, Nechepurenko A, Abdulkadyrov A, Paskeev D, Damrina E, Kulikova E, Terent'eva M, Stompel D, Tarasov D. Arguments to Apply Epinephrine for Pocket Hematoma Reduction. The MAITRE Study. J Atr Fibrillation. 2016 Jun 30;9(1):1391. doi: 10.4022/jafib.1391. eCollection 2016. PMID: 27909508; PMCID: PMC5089502.
Copy Download .nbib Format: NLM
Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age.

Journal of psychopharmacology (Oxford, England)

Hommers L, Scherf-Clavel M, Stempel R, Roth J, Falter M, Deckert J, Mattheisen M, Unterecker S, Gawlik M.
PMID: 33779379
J Psychopharmacol. 2021 Sep;35(9):1127-1133. doi: 10.1177/02698811211003477. Epub 2021 Mar 28.

BACKGROUND: Drug-induced prolongation of cardiac repolarization limits the treatment with many psychotropic drugs. Recently, the contribution of polygenic variation to the individual duration of the QT interval was identified.AIMS: To explore the interaction between antipsychotic drugs and the individual...

Cite
Hommers L, Scherf-Clavel M, Stempel R, et al. Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. J Psychopharmacol. 2021;35(9):1127-1133doi: 10.1177/02698811211003477.
Hommers, L., Scherf-Clavel, M., Stempel, R., Roth, J., Falter, M., Deckert, J., Mattheisen, M., Unterecker, S., & Gawlik, M. (2021). Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. Journal of psychopharmacology (Oxford, England), 35(9), 1127-1133. https://doi.org/10.1177/02698811211003477
Hommers, Leif, et al. "Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age." Journal of psychopharmacology (Oxford, England) vol. 35,9 (2021): 1127-1133. doi: https://doi.org/10.1177/02698811211003477
Hommers L, Scherf-Clavel M, Stempel R, Roth J, Falter M, Deckert J, Mattheisen M, Unterecker S, Gawlik M. Antipsychotics in routine treatment are minor contributors to QT prolongation compared to genetics and age. J Psychopharmacol. 2021 Sep;35(9):1127-1133. doi: 10.1177/02698811211003477. Epub 2021 Mar 28. PMID: 33779379; PMCID: PMC8436313.
Copy Download .nbib Format: NLM
The WISC and the SRA Primary Mental Abilities Test.

Child development

STEMPEL EF.
PMID: 13182743
Child Dev. 1953 Sep-Dec;24(3):257-61. doi: 10.1111/j.1467-8624.1953.tb04731.x.

No abstract available.

Cite
STEMPEL EF. The WISC and the SRA Primary Mental Abilities Test. Child Dev. 1953;24(3):257-61doi: 10.1111/j.1467-8624.1953.tb04731.x.
STEMPEL, E. F. (1953). The WISC and the SRA Primary Mental Abilities Test. Child development, 24(3), 257-61. https://doi.org/10.1111/j.1467-8624.1953.tb04731.x
STEMPEL, E F. "The WISC and the SRA Primary Mental Abilities Test." Child development vol. 24,3 (1953): 257-61. doi: https://doi.org/10.1111/j.1467-8624.1953.tb04731.x
STEMPEL EF. The WISC and the SRA Primary Mental Abilities Test. Child Dev. 1953 Sep-Dec;24(3):257-61. doi: 10.1111/j.1467-8624.1953.tb04731.x. PMID: 13182743.
Copy Download .nbib Format: NLM
A novel mutation in L1CAM causes a mild form of L1 syndrome: a case report.

Clinical case reports

Otter M, Wevers M, Pisters M, Pfundt R, Vos Y, Nievelstein RJ, Stumpel C.
PMID: 28781826
Clin Case Rep. 2017 Jun 15;5(8):1213-1217. doi: 10.1002/ccr3.1038. eCollection 2017 Aug.

Clinical geneticists, neurologists, psychiatrists, and other healthcare providers can learn from this case report that patients with a behavioral phenotype that includes a mild learning disability may also require a thorough examination, including brain MRI and whole-exome sequencing.

Cite
Otter M, Wevers M, Pisters M, et al. A novel mutation in L1CAM causes a mild form of L1 syndrome: a case report. Clin Case Rep. 2017;5(8):1213-1217doi: 10.1002/ccr3.1038.
Otter, M., Wevers, M., Pisters, M., Pfundt, R., Vos, Y., Nievelstein, R. J., & Stumpel, C. (2017). A novel mutation in L1CAM causes a mild form of L1 syndrome: a case report. Clinical case reports, 5(8), 1213-1217. https://doi.org/10.1002/ccr3.1038
Otter, Maarten, et al. "A novel mutation in L1CAM causes a mild form of L1 syndrome: a case report." Clinical case reports vol. 5,8 (2017): 1213-1217. doi: https://doi.org/10.1002/ccr3.1038
Otter M, Wevers M, Pisters M, Pfundt R, Vos Y, Nievelstein RJ, Stumpel C. A novel mutation in L1CAM causes a mild form of L1 syndrome: a case report. Clin Case Rep. 2017 Jun 15;5(8):1213-1217. doi: 10.1002/ccr3.1038. eCollection 2017 Aug. PMID: 28781826; PMCID: PMC5538050.
Copy Download .nbib Format: NLM
Author Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals.

Nature

Schwörer S, Becker F, Feller C, Baig AH, Köber U, Henze H, Kraus JM, Xin B, Lechel A, Lipka DB, Varghese CS, Schmidt M, Rohs R, Aebersold R, Medina KL, Kestler HA, Neri F, von Maltzahn J, Tümpel S, Rudolph KL.
PMID: 31363230
Nature. 2019 Aug;572(7769):E11-E15. doi: 10.1038/s41586-019-1455-1.

An Amendment to this paper has been published and can be accessed via a link at the top of the paper.

Cite
Schwörer S, Becker F, Feller C, et al. Author Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals. Nature. 2019;572(7769):E11-E15doi: 10.1038/s41586-019-1455-1.
Schwörer, S., Becker, F., Feller, C., Baig, A. H., Köber, U., Henze, H., Kraus, J. M., Xin, B., Lechel, A., Lipka, D. B., Varghese, C. S., Schmidt, M., Rohs, R., Aebersold, R., Medina, K. L., Kestler, H. A., Neri, F., von Maltzahn, J., Tümpel, S., & Rudolph, K. L. (2019). Author Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals. Nature, 572(7769), E11-E15. https://doi.org/10.1038/s41586-019-1455-1
Schwörer, Simon, et al. "Author Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals." Nature vol. 572,7769 (2019): E11-E15. doi: https://doi.org/10.1038/s41586-019-1455-1
Schwörer S, Becker F, Feller C, Baig AH, Köber U, Henze H, Kraus JM, Xin B, Lechel A, Lipka DB, Varghese CS, Schmidt M, Rohs R, Aebersold R, Medina KL, Kestler HA, Neri F, von Maltzahn J, Tümpel S, Rudolph KL. Author Correction: Epigenetic stress responses induce muscle stem-cell ageing by Hoxa9 developmental signals. Nature. 2019 Aug;572(7769):E11-E15. doi: 10.1038/s41586-019-1455-1. PMID: 31363230.
Copy Download .nbib Format: NLM
Phenotyping of Mice with Heart Specific Overexpression of A.

Frontiers in pharmacology

Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J.
PMID: 29403384
Front Pharmacol. 2018 Jan 22;9:13. doi: 10.3389/fphar.2018.00013. eCollection 2018.

No abstract available.

Cite
Boknik P, Drzewiecki K, Eskandar J, et al. Phenotyping of Mice with Heart Specific Overexpression of A. Front Pharmacol. 2018;9:13doi: 10.3389/fphar.2018.00013.
Boknik, P., Drzewiecki, K., Eskandar, J., Gergs, U., Grote-Wessels, S., Fabritz, L., Kirchhof, P., Müller, F. U., Stümpel, F., Schmitz, W., Zimmermann, N., Kirchhefer, U., & Neumann, J. (2018). Phenotyping of Mice with Heart Specific Overexpression of A. Frontiers in pharmacology, 913. https://doi.org/10.3389/fphar.2018.00013
Boknik, Peter, et al. "Phenotyping of Mice with Heart Specific Overexpression of A." Frontiers in pharmacology vol. 9 (2018): 13. doi: https://doi.org/10.3389/fphar.2018.00013
Boknik P, Drzewiecki K, Eskandar J, Gergs U, Grote-Wessels S, Fabritz L, Kirchhof P, Müller FU, Stümpel F, Schmitz W, Zimmermann N, Kirchhefer U, Neumann J. Phenotyping of Mice with Heart Specific Overexpression of A. Front Pharmacol. 2018 Jan 22;9:13. doi: 10.3389/fphar.2018.00013. eCollection 2018. PMID: 29403384; PMCID: PMC5786519.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 32 entries